MRDas an Early Indicator of SurvivalCould Fast-Track Conditional Approval for New Treatments of AML

In this article, Jesse Tettero, MD, PhD, Amsterdam University Medical Center, emphasizes the patient-level link between MRD and survival, the use of MRD as an intermediate endpoint that can reasonably be expected to predict long-term outcomes in intensively treated patients with acute myeloid leukemia. If MRD is accepted as an intermediate endpoint it could speed AML drug development without compromising the quality of evidence.